We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio In a cohort of patients with HF with ...

Please provide your email address to receive an email when new articles are posted on . “We were surprised and disappointed, and stared at the data for a long time, partly in disbelief,” Mann, who is ...

This study evaluated levels of 4 biomarkers associated with heart failure with reduced ejection fraction (HFrEF) before and after treatment with the angiotensin receptor neprilysin inhibitor ...

At present, there are no approved therapies for pre–heart failure with preserved ejection fraction (pre-HFpEF); instead, cardiovascular risk factor management is often utilized in this patient ...

Data from an open-label, fixed-sequence study showed that although sacubitril inhibited organic anion-transporting polypeptides (OATP)1B1 and OATP1B3 in vitro, this did not translate to any clinically ...

Confident prediction of who will or will not experience side effects from a cornerstone heart failure therapy continues to elude researchers, even as they showed that some real-world patients were ...

Heart failure patients unable to reach the target dose of angiotensin receptor/neprilysin inhibitor (ARNI) therapy still reaped gains in health status a year later, according to a post hoc analysis of ...

A cost-effective analysis of sacubitril-valsartan treatment in patients with New York Heart Association (NYHA) class II- to IV heart-failure found the treatment can provide a reasonable value in ...

The PARADISE-MI trial comparing sacubitril/valsartan to ramipril in patients with left ventricular dysfunction after myocardial infarction (MI) and clinical heart failure led off the late-breaking ...

Prague, Czechia – 21 May 2023: Sacubitril/valsartan leads to greater reduction in plasma NT-proBNP levels compared to valsartan alone after stabilisation for worsening heart failure in patients with ...